Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$4.6M, compared with -$3.98M a year earlier. Trailing-twelve-month EBITDA was -$43.15M.

Context

  • EBITDA amounted to 466.8% of revenue in FY2025, up 277.6 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$9.2M (+86.5%) for the fiscal year ending Dec 2026, a step up from the -278.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.6M-9.5% QoQ
Last fiscal yearDec 2025
-$67.95M-278.1% YoY
LTMMar 2026
-$43.15M-177.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.6%+28.5%+44.1 pp
1 year-278.1%+86.5%+364.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(67.95M) USD
Year-over-year change
-278.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 EBITDA of -$43.15M is the highest of the 4 companies compared; the peer median is -$77.62M.
  • Its year-over-year change of -177.1% is the 3rd highest of 4, against a peer median of -86.2%.
  • EBITDA amounts to 291.9% of revenue for LCTX, versus a peer median of 164.9%.
LCTX Competitors Peer median
EBITDA for LCTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-$43.15M -177.1%—291.9%
MESOMesoblast LimitedLTM Jun 2026-$45.01M +22.6%—37.4%
CELUCelularity Inc.LTM Dec 2025-$77.62M -86.2%—292.4%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$89.9M -1211.1%——
Peer median (excluding LCTX) -$77.62M-86.2%—164.9%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.9M14.7M8.95M9.5M14.56M
Cost of Revenue1.43M728K671K334K845K
Gross Profit2.47M13.98M8.27M9.17M13.71M
Gross Margin63.4%95.0%92.5%96.5%94.2%
Research & Development33.91M13.99M15.71M12.47M17.73M
Selling, General & Admin18.21M22.51M17.3M18.17M18.46M
Operating Expenses51.68M36.5M33.01M30.64M35.49M
Depreciation & Amortization873K727K692K609K699K
EBITDA(42.4M)(25.09M)(22.59M)(17.97M)(67.95M)
EBITDA Margin-1088.2%-170.6%-252.5%-189.2%-466.8%
Operating Income(49.21M)(22.52M)(24.73M)(21.48M)(21.78M)
Operating Margin-1263.1%-153.2%-276.5%-226.1%-149.6%
Interest Income2K829K1.63M1.72M1.69M
Interest Expense00000
Other Income / Expenses5.94M(3.29M)1.45M2.9M(46.87M)
Income Before Tax(43.27M)(25.81M)(23.28M)(18.58M)(68.65M)
Pre-Tax Margin-1110.6%-175.6%-260.3%-195.6%-471.6%
Income Tax Expense0541K(1.8M)0(5.11M)
Net Income(43.02M)(26.27M)(21.49M)(18.61M)(63.53M)
Net Margin-1104.2%-178.7%-240.2%-195.9%-436.5%
EPS (Basic)(0.26)(0.15)(0.12)(0.09)(0.28)
EPS (Diluted)(0.26)(0.15)(0.12)(0.09)(0.28)
Weighted Avg Shares164.5M169.79M172.66M200.19M230.12M
Weighted Avg Shares (Diluted)164.5M169.79M172.66M200.19M230.12M

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.